Batabulin

Batabulin

SCHEMBL18845

COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1F

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.54
ALDH1A1 P00352 4/20 0.54
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
HTT P42858 3/20 0.54
THRB P10828 2/20 0.54
MAPT P10636 2/20 0.54
SMN1; SMN2 Q16637 5/20 0.51
PKM P14618 2/20 0.51
TSHR P16473 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
HPGD P15428 1/20 0.49
CA1 P00915 5/20 0.49
CA2 P00918 5/20 0.49
HTR6 P50406 1/20 0.47
CYP1A2 P05177 1/20 0.46
GLA P06280 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Batabulin SCHEMBL29373304 1.00 LMNA (0.54) LMNAALDH1A1MEN1KMT2AHTT
Batabulin SCHEMBL6086887 0.98 LMNA (0.53) LMNAALDH1A1MEN1KMT2AHTT
Batabulin SCHEMBL6089508 0.98 LMNA (0.53) LMNAALDH1A1MEN1KMT2AHTT
SCHEMBL22909526 0.93 LMNA (0.51) LMNAALDH1A1MEN1KMT2AHTT
SCHEMBL29671221 0.93 LMNA (0.51) LMNAALDH1A1MEN1KMT2AHTT
SCHEMBL28762050 0.93 LMNA (0.51) LMNAALDH1A1MEN1KMT2AHTT
SCHEMBL31034621 0.93 CA1 (0.55) LMNAALDH1A1MEN1KMT2AHTT
Batabulin SCHEMBL7103854 0.92 LMNA (0.48) LMNAALDH1A1MEN1KMT2AHTT
SCHEMBL6673920 0.92 HTR6 (0.50) LMNAALDH1A1MEN1KMT2AHTT
SCHEMBL22909294 0.92 LMNA (0.50) LMNAALDH1A1MEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3730 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577255-B2 MDM2-based modulators of proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-03-17 US claimed
EP-4704832-A2 BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS Biohaven Therapeutics Ltd. (VG) 2026-03-11 EP claimed
US-20260022117-A1 COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS ARVINAS OPERATIONS INC (US) 2026-01-22 US claimed
US-12485178-B2 Bifunctional small molecules to target the selective degradation of circulating proteins YALE UNIVERSITY (US) 2025-12-02 US claimed
US-20250332274-A1 BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS UNIV YALE (US) 2025-10-30 US claimed
EP-4637751-A2 FOXM1 INHIBITORS AND THEIR USE IN TREATING CANCERS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2025-10-29 EP claimed
US-12364682-B2 Use of tegaserod in preparation of anti-tumor drug QINGDAO HAIJI BIOMEDICINE CO., LTD. (CN) 2025-07-22 US claimed
US-12364766-B2 Bifunctional small molecules to target the selective degradation of circulating proteins YALE UNIVERSITY (US) 2025-07-22 US claimed
CN-119591543-A Bis-aminoquinolines and nano-formulations for cancer treatment 加利福尼亚大学董事会 2025-03-11 CN claimed
US-20250059301-A1 Fusion Protein Construct NORTHWESTERN UNIVERSITY 2025-02-20 US claimed
US-6306615-B1 CONTACTING SAMPLE WITH ANTIBODY THAT SPECIFICALLY BINDS TO THE BETA-TUBULIN ISOTYPE MODIFIED AT THE CYSTEINE RESIDUE AT AMINO ACID POSITION 239 AND DETECTING THE ANTIBODY TULARIK INC. 2001-10-23 US claimed
WO-2001013122-A2 METHOD FOR MONITORING BETA TUBULIN ISOTYPE MODIFICATION TULARIK INC. (US) 2001-02-22 WO claimed
JP-2000515545-A 2000-11-21 JP claimed
EP-0939627-A4 PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS TULARIK INC (US) 2000-10-04 EP claimed
EP-0939627-A1 PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS TULARIK, INC. (US) 1999-09-08 EP claimed
EP-0896533-A4 PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS TULARIK INC (US) 1999-04-28 EP claimed
US-5880151-A TREATING OR PREVENTING DISEASE CHARACTERIZED BY HIGH LEVELS OF LOW DENSITY LIPOPROTEIN PARTICLES OR CHOLESTEROL IN BLOOD TULARIK INC. (US) 1999-03-09 US claimed
EP-0896533-A2 PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS TULARIK, INC. (US) 1999-02-17 EP claimed
WO-1998005315-A1 PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS TULARIK, INC. (US) 1998-02-12 WO claimed
WO-1997030677-A2 PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS TULARIK, INC. (US) 1997-08-28 WO claimed